Abstract
Immune checkpoint inhibitors (ICIs) are first-line treatments for melanoma in both the metastatic and adjuvant settings.1 The success of ICIs in the treatment of melanoma is unparallelled yet tempered by the potential development of off-target effects, termed immune-related adverse events (irAEs).2 IrAEs affecting bone and its metabolism, including osteoporosis and fracture, remain infrequently described and poorly understood. Cancer treatment-induced bone loss due to androgen deprivation therapy, aromatase inhibitors and ovarian suppression therapy is well recognised, with established guidelines to assist clinicians in making informed decisions regarding prevention, monitoring and treatment.3 Given the increasing survival associated with ICIs and the potential morbidity and mortality associated with major osteoporotic fractures (MOFs), there is a growing urgency to quantify the potential risk ICIs may pose to bone health and mitigate it if possible.

This publication has 9 references indexed in Scilit: